Global pharmaceutical company Eli Lilly has entered into strategic collaborations with software firms Schrödinger and Revvity to expand the use of its AI-based drug discovery platform, TuneLab, across the biotech sector.
The agreements will integrate Lilly’s AI drug discovery models into Schrödinger’s LiveDesign software and Revvity’s Signals platform, giving researchers broader access to advanced artificial intelligence tools designed to accelerate early-stage drug development.
Under the deal with Schrödinger, TuneLab will be incorporated into the LiveDesign environment, a cloud-based platform that supports chemists in designing compounds and predicting key drug properties such as absorption and distribution. Existing LiveDesign users are expected to gain access to TuneLab workflows in the first quarter of 2026, with wider availability planned later in the year.
The collaboration with Revvity will make TuneLab models available through the Revvity Signals Xynthetica offering, which integrates predictive modeling into drug discovery workflows. Both Lilly and Revvity are co-funding access for selected users, enabling scientists to harness the AI platform within Revvity’s R&D data environment while protecting proprietary research via privacy-preserving federated learning techniques.
These partnerships come amid a broader industry shift toward AI-assisted drug discovery, which aims to shorten development timelines and enhance predictive capabilities in early research phases. Lilly’s TuneLab platform, originally launched to give biotech firms access to models trained on extensive proprietary research data, reflects the company’s efforts to position AI at the centre of modern pharmaceutical R&D.
By bringing its AI models into established informatics software used by discovery teams worldwide, Lilly and its partners expect to speed up candidate identification and improve collaboration between computational and experimental workflows, advancing the pace of novel therapy development.
